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in FH was undertaken in 2004-2014 reviewing FH registries, PubMed and refer-
ence citations. Papers were assessed for bias using Newcastle-Ottawa scale. The 
literature-based FH relative risk (RR) was calculated. To validate the RR, a 10-year 
baseline risk of CV events was estimated for Rutherford-2 clinical trial population. 
The RR was used to adjust D’Agostino 2008 (primary prevention) and Wilson 2012 
(secondary prevention) baseline risk estimates. Sensitivity analyses varying patient 
characteristics were conducted. Results: Out of 796 identified publications, 14 
manuscripts met inclusion criteria. Danish population-based study (Benn 2012) 
showed the least risk of bias by directly comparing FH and non-FH populations in 
the same study and evaluating both fatal and non-fatal CV events. Subjects treated 
and untreated with lipid lowering therapy had odds ratio for coronary artery disease 
at 10.3 (95% CI: 7.8-13.8) and 13.2 (95% CI: 10.0 – 17.4), respectively. The FH RR of 
5.9 (5.0-6.9) and rate ratio of 7.1 (5.7-8.7) was calculated by pooling statin and no-
statin groups. Pooling the treated and untreated groups was introduced to mimic 
real world, accounting for the mix of primary and secondary prevention patients 
as well as different treatment paradigms. Combining the derived RR with the risk 
predicted by equations yielded a 55% 10-year baseline risk for Rutherford-2 FH 
patients. Patient characteristics such as proportion of patients receiving second-
ary prevention or age had an impact on estimated risk. ConClusions: Benn 2012 
provides estimates of increased CV risk for FH with the least bias. Estimated risk 
for Rutheford-2 patients is plausible for this high risk population. The derived RR 
seems acceptable for the use in economic modeling.
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objeCtives: To analyze survival and rehospitalization after a first hospitalization 
for heart failure (HF) in France. Methods: Analysis was based on EGB (“Echantillon 
Généraliste des Bénéficiaires”) database, a permanent random sample (1/97) of the 
French national healthcare insurance system database (SNIIRAM), linked with the 
national hospital discharge summary database (PMSI). Selected patients were adults 
(≥ 18 years) with a first HF hospitalization (ICD-10 codes: I-50/I-110/I-130/I-132) 
over a 3-years period (from 1st January 2009 to 31st December 2011). Patients were 
observed until death or 31stDecember 2013. Results: For analyses, 2,173 patients 
were included. Average age was 79 years (56% ≥ 80 years; 44% < 80 years) and sex 
ratio was close to parity (51% of woman; 49% of men). Average length of stay for 
the first HF hospitalization was 9.2 days (SD= 7.5 days) and 81% of these stays were 
strongly related to “heart failure or circulatory shock” (French DRG code: 05M09). 
The HF management was not optimal, with few cardiologist visits within the year 
prior the first HF hospitalization and low rates of prescription of HF recommended 
drugs. The median survival time was 37 months following the first HF hospitaliza-
tion and median time to rehospitalization was 15 months after the first HF hospi-
talization. The mortality and rehospitalization following the first HF hospitalization 
were both dramatically increased in older patients (≥ 80 years): respectively HR= 2.57 
(95%IC= [2.27-2.92]; p< 0.001) and HR= 1.68 (95%IC 1.51-1.87; p< 0.001). However, these 
events were both reduced in patients who visited a cardiologist during the year prior 
the first HF hospitalization: respectively HR= 0,84 (95%IC= [0.74-0.94]; p= 0.0036) and 
HR= 0.89 (95%IC= [0.80-0.99]; p= 0.0278). No significant difference on mortality or on 
rehospitalization was observed according to sex or treatments. ConClusions: 
Cardiologist visits remain at a very low frequency in this HF population. Better 
referring these patients to cardiologists should consolidate their management and 
thus reduce rehospitalization and mortality.
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objeCtives: More than 600,000 Canadians are afflicted with chronic heart fail-
ure (CHF), which is associated with high hospitalization and mortality rates. The 
objective of this study is to evaluate the mean cost ($CAD) and length of stay (LOS) 
amongst CHF patients treated in emergency departments (ED), stratified by sur-
vival and death outcomes. This abstract builds upon previously presented research 
to evaluate the costs of hospitalization due to CHF in a Canadian acute care set-
ting. Methods: Hospital discharge abstracts recorded between 2009 and 2013 from 
the Canadian Institute for Health Information’s Discharge Abstract Database and 
National Ambulatory Care Reporting System database were analyzed using a ret-
rospective cross-sectional study design. The two databases contain Canadian ED, 
acute care, and same-day surgery discharge abstracts. Discharge abstracts with 
congestive heart failure (ICD-10 code I50.0) recorded as the most responsible rea-
son for ED hospitalization amongst patients aged ≥ 18 were included in the study. 
Discharge abstracts with missing demographics, or absent without leave or against 
medical advice discharge status were excluded from the study. Results: 126,498 
ED discharge abstracts were included, with 99.8% of the visits ending in patient 
survival at discharge. The national mean CHF ED visit cost was $628, with survival 
outcomes incurring $628 and death outcomes incurring $502. The national mean 
CHF ED visit length of stay of was 0.56 days with survival outcomes requiring 0.57 
days and death outcomes requiring 0.16 days. The mean ED visit cost decreased with 
age with 18 to 34, 35 to 64, and 65+ incurring $670, $619, and $629 respectively. In 
contrast, the mean LOS increased with age: 18 to 34, 35 to 64 and 65+ experienced 
0.48, 0.50, and 0.58 days respectively. ConClusions: CHF ED visits are associated 
with significant healthcare cost and time investments, which provide an opportu-
nity for interventions that reduce the healthcare burden.
incremental net monetary benefit of £16 (£-406 to £329) at a willingness to pay of 
£20,000 per QALY. Dabigatran and apixaban had an incremental net monetary ben-
efit; £-320 (£-2,844 to £638) and £-686 (£-2,458 to £266) respectively. ConClusions: 
Rivaroxaban had the highest net monetary benefit at a willingness to pay threshold 
of £20,000 for primary prevention (THR and TKR). However, there was substantial 
uncertainty around these results in both populations.
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objeCtives: To evaluate the cost-effectiveness, from an Australian health sys-
tem perspective, of nivolumab versus ipilimumab for treatment of patients with 
previously-untreated, BRAF wild-type (WT) advanced melanoma (AM), comprising 
unresectable and/or metastatic melanoma). Methods: A state-transition Markov 
model with 3 health states (‘Alive, pre-progression’, ‘Alive, post progression’ and 
‘Dead’) and 12-week cycles was constructed to simulate the history of BRAF-WT 
Australian patients with AM. A 5% annual discount rate was applied to costs and 
health measures. A 10-year time horizon was selected to capture the long-term 
survival achieved with immunotherapy agents. For the Nivolumab Group, risks of 
progression and death were based on those observed in the Nivolumab arm of 
study CA209-066 (nivolumab versus dacarbazine). Log-logistic functions were used 
to extrapolate trial data up to 10 years based on AIC and clinical plausibility. For 
the Ipilimumab Group, transition probabilities were derived from applying hazard 
ratios (HRs) to the corresponding transition probabilities in the Nivolumab Group. 
In the absence of head-to-head evidence, HRs were calculated by indirect compari-
son of nivolumab versus ipilimumab using published data. AM management costs 
were estimated by survey of Australian clinicians. Ipilimumab costs were based on 
prices reimbursed under the Pharmaceutical Benefits Scheme (PBS) of Australia.
Nivolumab costs were based on the expected reimbursed price under the PBS per 
course of treatment. Utilities were determined using EQ-5D data from study CA209-
066. Probabilistic sensitivity analyses were undertaken using variations to key input 
parameters. Results: Compared to ipilimumab, nivolumab therapy over 10 years 
would lead to an improvement in survival of 1.58 years and 1.30 QALYs per per-
son, at a (discounted) net cost of AUD$77,119 per person. These equate to ICERs of 
AUD$48,851 per year of life saved and AUD$59,311 per QALY saved. ConClusions: 
Compared with ipilimumab, nivolumab represents a cost-effective means of improv-
ing outcomes among Australian patients with AM.
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objeCtives: Aclidinium/formoterol 400/12 µg (FDC 400/12 µg), is a long-acting mus-
carinic antagonist (LAMA) and a long-acting β 2-agonist (LABA) in a fixed-dose com-
bination used in the management of patients with chronic obstructive pulmonary 
disease (COPD). This study aimed to assess the cost-effectiveness of FDC 400/12 µg 
against the LAMA, aclidinium bromide 400 µg (AB 400 µg). Methods: A 5 health 
state Markov transition model, with monthly cycles, was developed using MS Excel 
to simulate the clinical course of patients with moderate to severe COPD treated with 
FDC 400/12 µg versus AB 400 µg. Health states were based on severity levels defined 
by GOLD 2010 criteria. The analysis was a head to head comparison without step-
up-therapy, from the NHS Scotland perspective, over a 5 year time horizon. Clinical 
data on the initial lung function improvement was provided by a pooled analysis of 
the ACLIFORM and AUGMENT trials. Resource use (management and event costs) and 
utilities were health state specific. Costs and effects were discounted at an annual 
rate of 3.5%. The outcome of the analysis was cost (£) per quality adjusted life year 
(QALY) gained. The analysis included one way and probabilistic sensitivity analyses 
to investigate the impact of parameter variability on model outputs. Results: FDC 
400/12 µg provided marginally higher costs (£41) and more QALYs (0.014), resulting 
in an incremental cost-effectiveness ratio of £2,976. Sensitivity analyses indicated 
results were generally robust to key parameter variation. The main drivers were mean 
baseline FEV1, risk of exacerbation, FEV1 improvement of FDC 400/12 µg and lung 
function decline. The probability of FDC 400/12 µg be cost-effective (using a willing-
ness to pay threshold of £20,000/QALY) versus AB 400 µg was 79%. ConClusions: 
In the Scottish setting, aclidinium/formoterol 400/12 µg can be considered a cost-
effective treatment option in patients with COPD versus aclidinium 400 µg.
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objeCtives: To derive an estimate for increased cardiovascular (CV) risk in familial 
hypercholesterolemia (FH) patients for use in economic analyses. Methods: A 
literature search reporting CV risk, rates, odds or ratios of mortality and morbidity 
